Weed (BUDZ) Income from Continuing Operations (2010 - 2026)
Weed's (BUDZ) quarterly Income from Continuing Operations came in at 175256.0 in Q1 2026, up 60.21% year-on-year from 109391.26 in Q1 2025, and up 91.74% quarter-over-quarter from 2122328.0 in Q4 2025.
Weed (BUDZ) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Weed's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 175256.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 60.21% year-over-year to 175256.0 in Q1 2026; TTM through Mar 2026 was 2479146.0, a 217.63% decrease from a year earlier, with the FY2025 full-year figure at 2744346.0, down 437.35% from the prior year.
- Income from Continuing Operations grew to 175256.0 in Q1 2026 per BUDZ's latest filing, from 2122328.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 734248.0 in Q3 2023 and bottomed at 3986741.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 192312.0 (2022), against an average of 989428.18.
- Across the five-year window, Income from Continuing Operations sank 1543.81% in 2022 and soared 124.53% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 192312.0 in 2022, then slumped by 105.07% to 394368.0 in 2023, then soared by 66.22% to 133224.0 in 2024, then slumped by 1493.05% to 2122328.0 in 2025, then surged by 91.74% to 175256.0 in 2026.
- Per Business Quant, the three latest BUDZ Income from Continuing Operations figures stand at 175256.0 (Q1 2026), 2122328.0 (Q4 2025), and 73946.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Weed | 3.72 Mn | 3.72 Mn | - | -175,256.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175,256.00 |
| Dec 31, 2025 | -2.12 Mn |
| Sep 30, 2025 | -73,946.00 |
| Jun 30, 2025 | -107,616.00 |
| Mar 31, 2025 | -440,455.00 |
| Dec 31, 2024 | -133,224.00 |
| Sep 30, 2024 | -95,887.00 |
| Jun 30, 2024 | -110,953.00 |
| Mar 31, 2024 | -170,652.00 |
| Dec 31, 2023 | -394,368.00 |
| Sep 30, 2023 | 734,248.00 |
| Jun 30, 2023 | -3.99 Mn |
| Mar 31, 2023 | -197,014.00 |
| Dec 31, 2022 | -192,312.00 |
| Sep 30, 2022 | -2.99 Mn |
| Jun 30, 2022 | -3.08 Mn |
| Mar 31, 2022 | -3.28 Mn |
| Dec 31, 2021 | -467,504.00 |
| Sep 30, 2021 | -182,101.00 |
| Jun 30, 2021 | -1.22 Mn |